AngioDynamics, Inc. (ANGO) - 10-K Summary
Business Context and Reporting Period
Company: AngioDynamics, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended May 31, 2025
Business Overview: A diversified medical technology company focused on cardiovascular disease and cancer treatment. Operations are divided into two segments: Med Tech (high-growth technologies like Auryon, NanoKnife, and Thrombus Management) and Med Device (vascular access, ports, and oncology products). The company is executing a strategic restructuring to shift from a manufacturing-heavy model to an outsourced model to improve margins.
Key Financial Metrics
| Metric | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Net Sales | $292.5 million | $303.9 million | (3.8%) |
| Gross Margin | 53.9% | 50.9% | +300 bps |
| Net Loss | $(34.0) million | $(184.3) million | Improvement of $150.3M |
| Loss Per Share (Diluted) | $(0.83) | $(4.59) | Improvement of $3.76 |
| Cash Flow from Operations | $(10.1) million | $(28.2) million | Improvement of $18.1M |
| Cash and Equivalents | $55.9 million | $76.1 million | $(20.2) million |
| Debt | $0 (Outstanding) | $0 (Outstanding) | N/A |
Segment Performance:
- Med Tech: Revenue increased 19.0% to $126.7 million, driven by Auryon and Thrombus Management growth.
- Med Device: Revenue decreased 16.0% to $165.8 million, primarily due to divestitures.
Material Changes vs. Prior Period
- Divestitures: The decline in total revenue is largely attributable to the sale of the PICC and Midline businesses (to Spectrum Vascular) and the dialysis/BioSentry businesses (to Merit Medical), which collectively reduced sales by approximately $33.4 million compared to the prior year.
- Product Discontinuations: The RadioFrequency Ablation and Syntrax product lines were discontinued in February 2024.
- Goodwill Impairment: Fiscal 2024 included a non-cash goodwill impairment charge of $159.5 million. No such charge was recorded in Fiscal 2025, significantly improving the net loss comparison.
- Legal Settlements: Fiscal 2024 included a $19.3 million legal settlement with BD. Fiscal 2025 legal expenses related to litigation outside the normal course of business decreased by $34.2 million year-over-year.
- Restructuring: The company announced a manufacturing restructuring plan in Jan 2024, modified in Q2 2025 to maintain a Queensbury, NY presence for select operations. This plan is expected to generate $15.0 million in annual cost savings starting in Fiscal 2027.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Strategic Focus: Management is prioritizing the Med Tech segment (Auryon, NanoKnife, Thrombus Management) for growth.
- Regulatory Milestones: Received FDA 510(k) clearance for NanoKnife Prostate Tissue Ablation and CE mark for Auryon. CPT Category I codes for NanoKnife (prostate/liver) effective Jan 2026 and pancreas effective Jan 2027.
- Liquidity: The company entered a new $25.0 million secured revolving credit facility in May 2025 (no outstanding balance as of May 31, 2025). Management believes current cash and access to credit are sufficient for the next 12 months.
- Share Repurchase: A $15.0 million repurchase program was authorized in July 2024. The company repurchased $1.7 million of stock in Fiscal 2025, with $13.3 million remaining available.
Risks and Contingencies:
- Manufacturing Transition: Risks associated with shifting to third-party manufacturers, including quality control, delivery timing, and potential cost increases.
- Legal Proceedings: Ongoing product liability claims regarding port products (approx. 162 claims consolidated in MDL). A settlement with BD requires annual minimum payments of $2.5 million starting in Fiscal 2025.
- Supply Chain: Dependence on single-source suppliers and exposure to tariffs, inflation, and geopolitical instability (e.g., China sourcing).
- Reimbursement: Reliance on third-party payors and potential pressure on pricing from Group Purchasing Organizations (GPOs).
Investor Verification Checklist
- Divestiture Impact: Verify the extent to which the $33.4 million revenue decline is permanent versus temporary, and assess the timeline for Med Tech growth to offset these losses.
- Restructuring Execution: Monitor the progress of the manufacturing footprint optimization and the realization of the projected $15.0 million annual cost savings starting in Fiscal 2027.
- Legal Exposure: Review the status of the consolidated port product liability litigation and the specific terms of the BD settlement (including potential contingent payments).
- Cash Burn Rate: Analyze the operating cash flow burn of $10.1 million against the $55.9 million cash balance to assess runway without additional financing or significant revenue acceleration.
- Regulatory Approvals: Track the commercial uptake of the NanoKnife prostate ablation clearance and the Auryon system following the AMBITION BTK trial initiation.